Astra Wealth Partners LLC Acquires Shares of 329 Axon Enterprise, Inc $AXON

Astra Wealth Partners LLC bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 329 shares of the biotechnology company’s stock, valued at approximately $272,000.

A number of other institutional investors and hedge funds have also made changes to their positions in AXON. TCTC Holdings LLC raised its holdings in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 24 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of Axon Enterprise in the first quarter valued at about $31,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Axon Enterprise in the first quarter valued at about $32,000. Flaharty Asset Management LLC purchased a new stake in shares of Axon Enterprise in the first quarter valued at about $33,000. Finally, Hemington Wealth Management raised its holdings in shares of Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 0.9%

Shares of AXON opened at $732.23 on Monday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average is $731.05 and its two-hundred day moving average is $733.88. Axon Enterprise, Inc has a twelve month low of $422.38 and a twelve month high of $885.91. The firm has a market capitalization of $57.48 billion, a P/E ratio of 180.80, a PEG ratio of 29.49 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same period in the prior year, the business posted $1.20 earnings per share. The firm’s revenue for the quarter was up 32.6% compared to the same quarter last year. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the transaction, the chief financial officer directly owned 93,592 shares in the company, valued at approximately $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hadi Partovi acquired 1,358 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were acquired at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the completion of the purchase, the director owned 237,938 shares in the company, valued at approximately $176,074,120. This represents a 0.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 59,932 shares of company stock valued at $45,115,616 in the last ninety days. Company insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a report on Wednesday, October 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. Bank of America increased their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Raymond James Financial reissued an “outperform” rating and set a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Northland Securities set a $800.00 price target on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.